JPM24, Day 3 Overview: Gene editors talk business development; Roivant CEO has money to spend
After selling off Telavant to Roche for $7.1 billion last year, Roivant is flush with cash, with no need to raise funds.
The CEO explained how they plan to spend their capital, which sits at $7 billion, a significant strong position. The company utilised the meeting of investors, not to raise money, but to meet prospective partners and discuss new opportunity with their new position.
Intellia Therapeutics assured the FDA that its gene edits are safe and effective for patients. The company spoke about the launching of their preclinical reproductive toxicity study that has reported very successful. The company has also benefited from a regenerative medicine advanced therapy, providing them better communication with the FDA.
CRISPR Therapeutics are hot off the heels of their sickle cell gene therapy Casgevy. However, CEO Sam Kulkarni, Ph.D., said there is still room for business development in the gene editing biotech’s future.
Editas Medicine’s Chief Financial Officer Erick Lucera spoke on the company after Vertex Pharmaceuticals entered a deal worth $100 million to the rights of Editas’ Cas9 gene-editing tech last month. He said in terms of potential deals Editas can either gain access to technology that other companies have via licensing or provide non-dilutive capital to continue to fund Editas’ product development.
Read more about Day 3:
#jpm2024 #roivant #genetherapy #therapeutics